Manish Bais, DVM, PhD
Assistant Professor
Boston University Henry M. Goldman School of Dental Medicine
Dept of Translational Dental Medicine

PhD, Indian Veterinary Research Institute (IVRI)
DVM, Nagpur Veterinary College
MVSc, Indian Veterinary Research Institute (IVRI)




Dr. Manish Bais is a Research Assistant Professor in the Department of Molecular and Cell Biology at Boston University’s Henry M. Goldman School of Dental Medicine. Dr. Bais is also an important member of the Oral Cancer Research Initiative (OCRI). With funding from the OCRI, Dr. Bais travelled to the National Institute of Dental and Craniofacial Research in the summer of 2013 to receive mouse model training in the lab of Dr. Roberto Weigert. Dr. Bais has made large contributions to the initiative with the development of an orthotropic oral cancer mouse model.

The orthotropic nude mouse models of non-metastatic and metastatic tongue cancer that Dr. Bais has developed will facilitate mechanistic in vivo studies and preclinical testing of novel targets for anti-oral cancer therapy. Specifically, he has generated mice with non-metastatic tongue tumors following injection of human tongue squamous cell carcinoma (OSCC) CAL27 cells into tongues of nude mice. In addition, Dr. Bais has generated mice with tongue tumors formed by injection of SCC2 cells that metastasize to lung, bone and liver, sites of metastases of human tongue cancers.

Dr. Bais is collaborating with many OCRI investigators including Dr. Maria Kukuruzinska, Dr. Philip Trackman, Dr. Bob Varelas and Dr. David Sherr. This animal model and other models still in progress can help us to better understand the biology of oral cancer as well as provide new therapeutic opportunities in the treatment of this deadly disease.

Member
Boston University
BU-BMC Cancer Center


Member
Boston University
Evans Center for Interdisciplinary Biomedical Research


Member
Boston University
Genome Science Institute


Research Associate Professor
Boston University Henry M. Goldman School of Dental Medicine
Molecular & Cell Biology




Mechanism of LSD1 Function and Its Therapeutic Application for Progressive Oral Malignancy
03/15/2022 - 01/31/2027 (PI)
NIH/National Institute of Dental & Craniofacial Research
1R01DE031413-01

Epigenetic Targeting of LSD1 OSCC for Therapy
09/01/2018 - 08/31/2021 (PI)
NIH/National Institute of Dental & Craniofacial Research
5R21DE026892-02

LOXL2 in Temporomandibular Joint Osteoarthritis
08/01/2015 - 07/31/2018 (PI)
NIH/National Institute of Dental & Craniofacial Research
5R03DE025274-02



Title


Yr Title Project-Sub Proj Pubs
2019 Epigenetic targeting of LSD1 for OSCC Therapy 5R21DE026892-02 1
2018 Epigenetic targeting of LSD1 for OSCC Therapy 1R21DE026892-01A1 1
2016 LOXL2 in Temporomandibular Joint Osteoarthritis 5R03DE025274-02 6
2015 LOXL2 in Temporomandibular Joint Osteoarthritis 1R03DE025274-01 6

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Alhousami T, Diny M, Ali F, Shin J, Kumar G, Kumar V, Campbell JD, Noonan V, Hanna GJ, Denis GV, Monti S, Kukuruzinska MA, Varelas X, Bais MV. Inhibition of LSD1 Attenuates Oral Cancer Development and Promotes Therapeutic Efficacy of Immune Checkpoint Blockade and YAP/TAZ Inhibition. Mol Cancer Res. 2022 May 04; 20(5):712-721.View Related Profiles. PMID: 35105672
     
  2. Joshi VG, Chindera K, Bais MV, Sajjanar B, Tiwari AK, Kumar S. Novel peptide (RATH) mediated delivery of peptide nucleic acids for antiviral interventions. Appl Microbiol Biotechnol. 2021 Sep; 105(18):6669-6677. PMID: 34427763
     
  3. Tashkandi MM, Alsaqer SF, Alhousami T, Ali F, Wu YC, Shin J, Mehra P, Wolford LM, Gerstenfeld LC, Goldring MB, Bais MV. LOXL2 promotes aggrecan and gender-specific anabolic differences to TMJ cartilage. Sci Rep. 2020 11 19; 10(1):20179.View Related Profiles. PMID: 33214607; PMCID: PMC7678826; DOI: 10.1038/s41598-020-77178-9;
     
  4. Chandler KB, Alamoud KA, Stahl VL, Nguyen BC, Kartha VK, Bais MV, Nomoto K, Owa T, Monti S, Kukuruzinska MA, Costello CE. ß-Catenin/CBP inhibition alters epidermal growth factor receptor fucosylation status in oral squamous cell carcinoma. Mol Omics. 2020 06 01; 16(3):195-209.View Related Profiles. PMID: 32203567; PMCID: PMC7299767; DOI: 10.1039/d0mo00009d;
     
  5. Tashkandi M, Ali F, Alsaqer S, Alhousami T, Cano A, Martin A, Salvador F, Portillo F, C Gerstenfeld L, Goldring MB, Bais MV. Lysyl Oxidase-Like 2 Protects against Progressive and Aging Related Knee Joint Osteoarthritis in Mice. Int J Mol Sci. 2019 Sep 27; 20(19). PMID: 31569601; PMCID: PMC6801581; DOI: 10.3390/ijms20194798;
     
  6. Bais MV. Impact of Epigenetic Regulation on Head and Neck Squamous Cell Carcinoma. J Dent Res. 2019 03; 98(3):268-276. PMID: 30615537; PMCID: PMC6385352; DOI: 10.1177/0022034518816947;
     
  7. Kartha VK, Alamoud KA, Sadykov K, Nguyen BC, Laroche F, Feng H, Lee J, Pai SI, Varelas X, Egloff AM, Snyder-Cappione JE, Belkina AC, Bais MV, Monti S, Kukuruzinska MA. Functional and genomic analyses reveal therapeutic potential of targeting ß-catenin/CBP activity in head and neck cancer. Genome Med. 2018 07 20; 10(1):54.View Related Profiles. PMID: 30029671; PMCID: PMC6053793; DOI: 10.1186/s13073-018-0569-7;
     
  8. Bais MV. Targeting oral cancer epigenome via LSD1. Aging (Albany NY). 2017 12 11; 9(12):2455-2456. PMID: 29232656; PMCID: PMC5764378; DOI: 10.18632/aging.101343;
     
  9. Trackman PC, Bais MV. Measurement of lysyl oxidase activity from small tissue samples and cell cultures. Methods Cell Biol. 2018; 143:147-156.View Related Profiles. PMID: 29310775
     
  10. Bais MV, Goldring MB. LOXL2 as a protective in osteoarthritis cartilage. Aging (Albany NY). 2017 Oct 27; 9(10):2024-2025. PMID: 29080554; PMCID: PMC5680553; DOI: 10.18632/aging.101317;
     
Showing 10 of 35 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 35 publications over 18 distinct years, with a maximum of 7 publications in 2017

YearPublications
20032
20041
20071
20081
20093
20101
20111
20121
20132
20143
20154
20161
20177
20181
20192
20202
20211
20221


Recent (within 3 months)

Could blocking or deleting a protein help prevent common oral cancers?

Medical Xpress 4/26/2022

2015-2017 RO3- NIH/ NIDCR: LOXL2 in TMJ osteoarthritis
2015-2016 Henry M. Goldman School of Dental Medicine: Lysine specific demethylase 1 inhibitor for improved personalized oral cancer therapy
2014-2015 CNN Pilot grant, Center for Nanoscience and Nanotechnology (CNN), Boston University: Nanodelivery Approaches for Targeting DPAGT1 and LSD1 for oral Squamous Cell Carcinoma therapy
2014-2015 CTSI, BUSDM: Patient-derived Tumors Orthotopic Oral Cancer Mouse Models
2012-2013 BUSDM seed funding: LOXL2 in Anabolic Response to TMJ-Osteoarthritis
Contact for Mentoring:

700 Albany St Ctr for Adv Biomed Res
Boston MA 02118
Google Map

617.358.4439
Download vCard

Bais's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
See all (222) concept(s)
_
Media Mentions
_
Co-Authors
See all (28) people
_
Similar People
See all (60) people
_
Same Department
Search Department